A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Rituximab versus Placebo in Combination with Rituximab in Treatment Naïve Subjects with Follicular Lymphoma
The purpose of this study is to compare the effects of ibrutinib plus rituximab with placebo plus rituximab on participants with Follicular Lymphoma.
Treatment Naive Follicular Lymphoma
60 Years and older
No prior treatment for Follicular Lymphoma
60 - 120
Healthy Volunteers Needed
Duration of Participation
If eligible you will receive the study treatment until your disease worsens or you have bad side effects.
Knight Cancer Institute Clinical Trials